Management options for children with attention-deficit/hyperactivity disorder: a regional perspective on value.
Use of comparative effectiveness information in local healthcare decisions can be confounded by variations in practice, barriers to access and population demographics. The New England Comparative Effectiveness Public Advisory Council was convened as a public deliberative panel that considers evidence on the comparative clinical effectiveness and comparative value of a variety of therapeutic interventions. The council is tasked with making summary judgments on the evidence and recommendations for applying the evidence in medical and drug coverage policy, as well as initiating educational efforts for patients and clinicians. The New England Comparative Effectiveness Public Advisory Council met in June 2012 to discuss management options for attention-deficit/hyperactivity disorder, guided by a recent comparative effectiveness review from the Agency for Healthcare Research and Quality and supplementary economic analyses conducted by the Institute for Clinical and Economic Review. This article summarizes the deliberations and reflects on lessons learned regarding use of region-specific economic analyses to guide decision-making.
Institute for Clinical & Economic Review, MGH Institute for Technology Assessment, 101 Merrimac Street, 10th Floor, Boston, MA 02114, USA.
Daniel A
DA
Ollendorf
Kristen
K
Migliaccio-Walle
Jennifer A
JA
Colby
Steven D
SD
Pearson
D001289:Attention Deficit Disorder with Hyperactivity / Q000191:economics / Q000628:therapy*; D002017:Budgets; D002648:Child; D002662:Child Health Services / Q000191:economics / Q000639:trends; D002675:Child, Preschool; D057186:Comparative Effectiveness Research; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D005544:Forecasting; D017048:Health Care Costs; D006801:Humans; D008484:Medicaid / Q000191:economics; D009511:New England; D016896:Treatment Outcome; D014481:United States